Britain's medicine regulator has approved the world's first weight-loss tablet form of semaglutide, branded as the Wegovy Pill. The development has generated significant public interest, with online pharmacies anticipating substantial waiting lists for the medication, which will initially be available only privately.
The approval follows a surge in demand for weight-loss drugs like Wegovy and Mounjaro, which are currently administered via self-injection. The pill form is also expected to be less expensive than the injections, potentially making it a more appealing option for many.
However, concerns have been raised regarding the Wegovy Pill's effectiveness and ease of use compared to the injectable versions. Semaglutide, the active ingredient, mimics a natural hormone that regulates appetite by increasing feelings of fullness and reducing hunger. While the injectable form has proven effective, the oral tablet form faces challenges.
Efficacy and Absorption Challenges
The oral formulation of semaglutide uses a special compound to protect the drug from stomach enzymes, which would typically destroy it before it can enter the bloodstream. Despite this innovation, studies suggest that the highest dose of the Wegovy Pill results in approximately 17% weight loss, falling short of the roughly 22% weight loss observed with the Mounjaro injection. This difference is significant, especially considering that not all patients achieve the average weight loss with injections, and some experience plateaus where the drug's effect diminishes.
Furthermore, the Wegovy Pill requires a strict daily dosing regimen. Patients must take the tablet on a completely empty stomach after at least an eight-hour fast. It can only be consumed with a small, specific amount of water (up to 120ml), and patients must refrain from eating or drinking anything for 30 minutes afterward. Failure to adhere to these instructions can impair drug absorption and limit weight loss. Experts predict that this demanding routine may be difficult for many patients to maintain consistently.
Side Effects and Potential Shortages
The side effects associated with the Wegovy Pill are similar to those of the injections and can include nausea, diarrhea, abdominal pain, constipation, and vomiting, particularly when starting the medication or increasing the dose. The pill contains a much higher concentration of semaglutide per dose than the injection to compensate for absorption limitations.
This increased concentration, coupled with the high anticipated demand for the oral form, raises concerns about potential shortages. Semaglutide has faced repeated global shortages due to high demand in recent years. If the Wegovy Pill becomes more popular than the injections, it could exacerbate these supply issues. Patients prescribed the pill would have limited alternatives, as no other approved weight-loss tablets currently exist.
A Niche for the Pill?
Despite these drawbacks, the Wegovy Pill may offer a vital alternative for specific patient groups. For individuals with a severe phobia of needles, who find self-injection impossible or extremely distressing, the availability of an oral option could be life-changing. For such patients, the pill could remove a significant barrier to accessing weight-loss treatment.
However, for a broader population of patients considering weight-loss medication, the reduced efficacy, complex dosing schedule, and potential for drug shortages make the injectable form of Wegovy a more attractive proposition. While the excitement surrounding the new pill is understandable, prospective users are advised to carefully consider its limitations.